CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 142 filers reported holding CYMABAY THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.69 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,838,996 | +46.4% | 1,129,376 | +7.5% | 4.74% | +18.0% |
| Q2 2023 | $11,498,792 | +21.7% | 1,050,118 | -3.0% | 4.02% | +28.8% |
| Q1 2023 | $9,444,789 | +31.7% | 1,083,118 | -5.3% | 3.12% | +10.8% |
| Q4 2022 | $7,169,939 | +58.7% | 1,143,531 | -11.4% | 2.81% | +123.0% |
| Q3 2022 | $4,517,000 | +11.6% | 1,290,511 | -6.0% | 1.26% | -26.1% |
| Q2 2022 | $4,048,000 | +2.3% | 1,372,244 | +7.9% | 1.71% | +169.5% |
| Q1 2022 | $3,957,000 | +4.3% | 1,272,244 | +13.4% | 0.63% | -54.0% |
| Q4 2021 | $3,793,000 | – | 1,122,244 | – | 1.38% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
| Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
| Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
| Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
| Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
| ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
| TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
| Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
| Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |